Physician profile
Sergio Sanchez
NPI 1962445494
$14,191.12
in general payments reported to CMS, 2019-2025
18 companies · $12K in 2025
The $12K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $338 · 2021: $372 · 2022: $162 · 2023: $518 · 2024: $783 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,245 · Food and Beverage: $2,465 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,300 · Travel and Lodging: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,245.00 |
| Food and Beverage | $2,465.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,300.00 |
| Travel and Lodging | $1,199.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11,054.82 | 2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $870.54 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $564.65 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $505.99 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.67 | 2023-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $241.64 | 2023-2025 | |
| Esperion Therapeutics, INC. | $159.27 | 2020-2021 | |
| Exact Sciences Corporation | $103.58 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $98.92 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $90.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $44.30 | 2024 | Zoryve |
| Amarin Pharma, INC. | $41.18 | 2020 | |
| Merck Sharp & Dohme LLC | $38.87 | 2020 | |
| Xeris Pharmaceuticals, INC. | $30.31 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.95 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.65 | 2024 | Dexcom G6 Transmitter |
| Intuity Medical INC | $18.33 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Pfizer INC. | $12.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.